USD 303.32
(0.0%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 60.44 Billion CHF | -4.49% |
2022 | 63.28 Billion CHF | 0.76% |
2021 | 62.8 Billion CHF | 7.68% |
2020 | 58.32 Billion CHF | -5.11% |
2019 | 61.46 Billion CHF | 8.13% |
2018 | 56.84 Billion CHF | 6.65% |
2017 | 53.29 Billion CHF | 5.38% |
2016 | 50.57 Billion CHF | 5.05% |
2015 | 48.14 Billion CHF | 1.44% |
2014 | 47.46 Billion CHF | 1.46% |
2013 | 46.78 Billion CHF | 2.82% |
2012 | 45.49 Billion CHF | 6.98% |
2011 | 42.53 Billion CHF | -10.41% |
2010 | 47.47 Billion CHF | -3.22% |
2009 | 49.05 Billion CHF | 7.53% |
2008 | 45.61 Billion CHF | -1.12% |
2007 | 46.13 Billion CHF | 9.73% |
2006 | 42.04 Billion CHF | 18.39% |
2005 | 35.51 Billion CHF | 13.55% |
2004 | 31.27 Billion CHF | 0.17% |
2003 | 31.22 Billion CHF | 5.03% |
2002 | 29.72 Billion CHF | 1.93% |
2001 | 29.16 Billion CHF | 1.71% |
2000 | 28.67 Billion CHF | 4.01% |
1999 | 27.56 Billion CHF | 11.78% |
1998 | 24.66 Billion CHF | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 15.37 Billion CHF | 0.0% |
2024 Q1 | 15.37 Billion CHF | -46.86% |
2023 FY | 60.44 Billion CHF | -4.49% |
2023 Q3 | 14.91 Billion CHF | -49.92% |
2023 Q4 | 28.93 Billion CHF | 94.05% |
2023 Q2 | 29.77 Billion CHF | 94.53% |
2023 Q1 | 15.3 Billion CHF | -50.6% |
2022 FY | 63.28 Billion CHF | 0.76% |
2022 Q4 | 30.98 Billion CHF | 94.18% |
2022 Q1 | 16.95 Billion CHF | -47.18% |
2022 Q2 | 32.29 Billion CHF | 90.53% |
2022 Q3 | 15.95 Billion CHF | -50.59% |
2021 Q1 | 16.06 Billion CHF | -44.68% |
2021 FY | 62.8 Billion CHF | 7.68% |
2021 Q3 | 16.85 Billion CHF | -45.11% |
2021 Q4 | 32.08 Billion CHF | 90.34% |
2021 Q2 | 30.71 Billion CHF | 91.16% |
2020 FY | 58.32 Billion CHF | -5.11% |
2020 Q1 | 15.18 Billion CHF | -51.0% |
2020 Q2 | 29.28 Billion CHF | 92.78% |
2020 Q3 | 14.98 Billion CHF | -48.83% |
2020 Q4 | 29.04 Billion CHF | 93.84% |
2019 Q4 | 30.99 Billion CHF | 93.73% |
2019 Q1 | 15.87 Billion CHF | 5.94% |
2019 Q2 | 15.87 Billion CHF | 0.0% |
2019 FY | 61.46 Billion CHF | 8.13% |
2019 Q3 | 16 Billion CHF | 0.78% |
2018 Q1 | 14.76 Billion CHF | 4.71% |
2018 FY | 56.84 Billion CHF | 6.65% |
2018 Q4 | 14.98 Billion CHF | 0.0% |
2018 Q3 | 14.98 Billion CHF | 1.5% |
2018 Q2 | 14.76 Billion CHF | 0.0% |
2017 Q2 | 13.77 Billion CHF | 0.0% |
2017 Q1 | 13.77 Billion CHF | 3.46% |
2017 FY | 53.29 Billion CHF | 5.38% |
2017 Q4 | 14.09 Billion CHF | 0.0% |
2017 Q3 | 14.09 Billion CHF | 2.36% |
2016 Q1 | 13 Billion CHF | 1.7% |
2016 FY | 50.57 Billion CHF | 5.05% |
2016 Q2 | 13 Billion CHF | 0.0% |
2016 Q4 | 13.31 Billion CHF | 0.0% |
2016 Q3 | 13.31 Billion CHF | 2.38% |
2015 FY | 48.14 Billion CHF | 1.44% |
2015 Q1 | 12.41 Billion CHF | -2.6% |
2015 Q4 | 12.78 Billion CHF | 0.0% |
2015 Q3 | 12.78 Billion CHF | 2.99% |
2015 Q2 | 12.41 Billion CHF | 0.0% |
2014 Q3 | 12.74 Billion CHF | 4.6% |
2014 FY | 47.46 Billion CHF | 1.46% |
2014 Q4 | 12.74 Billion CHF | 0.0% |
2014 Q2 | 12.18 Billion CHF | 0.0% |
2014 Q1 | 12.18 Billion CHF | 0.05% |
2013 FY | 46.78 Billion CHF | 2.82% |
2013 Q2 | 12.12 Billion CHF | 0.0% |
2013 Q3 | 12.18 Billion CHF | 0.45% |
2013 Q4 | 12.18 Billion CHF | 0.0% |
2013 Q1 | 12.12 Billion CHF | 0.0% |
2012 FY | 45.49 Billion CHF | 6.98% |
2011 FY | 42.53 Billion CHF | -10.41% |
2010 FY | 47.47 Billion CHF | -3.22% |
2009 FY | 49.05 Billion CHF | 7.53% |
2008 FY | 45.61 Billion CHF | -1.12% |
2007 FY | 46.13 Billion CHF | 9.73% |
2006 FY | 42.04 Billion CHF | 18.39% |
2005 FY | 35.51 Billion CHF | 13.55% |
2004 FY | 31.27 Billion CHF | 0.17% |
2003 FY | 31.22 Billion CHF | 5.03% |
2002 FY | 29.72 Billion CHF | 1.93% |
2001 FY | 29.16 Billion CHF | 1.71% |
2000 FY | 28.67 Billion CHF | 4.01% |
1999 FY | 27.56 Billion CHF | 11.78% |
1998 FY | 24.66 Billion CHF | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
AstraZeneca PLC | 46.91 Billion USD | -28.832% |
Bristol-Myers Squibb Company PFD CONV 2 | 45 Billion USD | -34.295% |
CSPC Pharmaceutical Group Limited | 31.45 Billion USD | -92.181% |
Clarus Therapeutics Holdings, Inc. | 13.95 Million USD | -432951.515% |
Novartis AG | 46.66 Billion USD | -29.535% |
PT Kalbe Farma Tbk. | 1.97 Billion USD | -2953.819% |